Jianyou Holdings’ subsidiary obtains FDA approval for relocation of daunorubicin hydrochloride injection production site
June 11, 2025
Source: drugdu
41
On June 9, Jianyou shares(603707) announced that its subsidiary Meitheal Pharmaceuticals, Inc. recently obtained the approval letter for the transfer of the production site of daunorubicin hydrochloride injection (20mg/4mL, ANDA No.: 065035) issued by the U.S. FDA, approving the production at Jianjin Pharmaceutical Co., Ltd. The drug is suitable for the treatment of adult acute non-lymphocytic leukemia and can be used in combination with other anticancer drugs.
The announcement mentioned that the company has invested about 830,000 yuan in research and development costs in the project of relocating the production site of daunorubicin hydrochloride injection. The newly approved product will be marketed in the United States and is expected to have a positive impact on the company's operating performance.
In the first quarter of 2025, Jianyou Shares achieved revenue of 885 million yuan and net profit attributable to shareholders of the parent company of 84.71 million yuan.
https://finance.eastmoney.com/a/202506093425522822.html
Copyright©2025 Ddu. All rights reserved.
Read more on
- the first of its kind to achieve the primary endpoint of mid-term analysis in nasopharyngeal carcinoma stage III clinical trials with iza bene July 4, 2025
- Gout treatment welcomes new choices! Changchun High tech’s first domestically approved injection of Fuxinqibai monoclonal antibody for market launch July 4, 2025
- this is the path to carbon neutrality July 4, 2025
- Dizal (Jiangsu) Pharmaceutical Co., Ltd. Voluntary Disclosure of Announcement Regarding Accelerated Marketing Approval of Suvoderm® by the U.S. FDA July 4, 2025
- Rare, Recurrent, and Still a Challenge July 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
